TOP-1630

N/A

Report date: 2024/05/14 20:00:10
NME

Base Information

Drug NameTOP-1630
Drug Alias NameTOP-1630
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase SRC inhibitorsP38 mitogen-activated protein kinase inhibitorsSpleen tyrosine kinase inhibitors +[5] 
TargetsP38 mitogen-activated protein kinaseTyrosine-protein kinase SRCTyrosine-protein kinase LCK +[5] 
Therapy Area/IndicationsDry Eye Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTopivert Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOra IncTopivert Pharma Ltd
Active IndicationsN/A
Inactive IndicationsDry Eye Syndromes

Other Information

ATC CodeN/A
Related LinksN/A